Progress of B-cell mature antigen-targeted chimeric antigen receptor T-cell therapy for multiple myeloma

VernacularTitle:靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展
Author: Yan YAN ¹ ; Quande LIN ; Yongping SONG
Author Information

1. 郑州大学附属肿瘤医院　河南省肿瘤医院血液科　河南省血液病研究所，郑州　450008
Keywords: Multiple myeloma; Chimeric antigen receptor T-cell; B-cell mature antigen
From: Journal of Leukemia & Lymphoma 2022;31(2):68-72
CountryChina
Language:Chinese
Abstract: Cell therapy as represented by chimeric antigen receptor T-cell (CAR-T) therapy has made many breakthroughs in the treatment of multiple myeloma (MM), especially autologous CAR-T targeting B-cell mature antigen (BCMA), bispecific CAR-T and universal CAR-T have achieved good curative effect in many clinical studies of MM. A variety of clinical studies with remarkable results were updated at the 63rd American Society of Hematology Annual Meeting.